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Abstract
Background Cebranopadol (a.k.a. GRT-6005) is a dually
acting nociceptin/orphanin FQ and opioid receptor agonist
that has been recently developed in Phase 2 clinical trials
for painful diabetic neuropathy or cancer pain. It also
showed analgesic properties in various rat models of pain
and had a better safety profile as compared to equi-anal-
gesic doses of morphine. Since antinociceptive properties
of cebranopadol have been studied mainly in rat models, in
the present study, we assessed analgesic activity of sub-
cutaneous cebranopadol (10 mg/kg) in various mouse pain
models.
Methods We used models of acute, tonic, and chronic pain
induced by thermal and chemical stimuli, with a particular
emphasis on pharmacoresistant chronic neuropathic pain
evoked by oxaliplatin in which cebranopadol was used
alone or in combination with simvastatin.
Key results As shown in the hot plate test, the analgesic
activity of cebranopadol developed more slowly as com-
pared to morphine (90–120 min vs. 60 min). Cebranopadol
displayed a significant antinociceptive activity in acute
pain models, i.e., the hot plate, writhing, and capsaicin
tests. It attenuated nocifensive responses in both phases of
the formalin test and reduced cold allodynia in oxaliplatin-
induced neuropathic pain model. Its efficacy was similar to
that of morphine. Used in combination and administered
simultaneously, 4 or 6 h after simvastatin, cebranopadol
did not potentiate antiallodynic activity of this cholesterol-
lowering drug. Cebranopadol did not induce any motor
deficits in the rotarod test.
Conclusion Cebranopadol may have significant potential
for the treatment of various pain types, including inflam-
matory and chemotherapy-induced neuropathic pain.
Keywords Cebranopadol  Pain models 
Neurogenic inflammation 
Chemotherapy-induced peripheral neuropathy 
Oxaliplatin  Simvastatin
Introduction
The International Association for the Study of Pain (IASP)
defines pain as an unpleasant sensory and emotional
experience associated with actual or potential tissue dam-
age, or described in terms of such damage. The sensation of
pain involves multiple signaling pathways, numerous
neurotransmitters, and other mediators that are involved in
the inhibitory or facilitatory control of pain intensity. These
mechanisms affect the perception of stimuli as non-painful
or painful, respectively, but their positive or negative
modulation of pain signaling is strongly dependent on the
receptor type involved and its location in the target tissue
(Argoff 2011).
In living organisms, endogenous opioids (endorphins,
enkephalins, and dynorphins) are key molecules in the
descending pain suppression pathways. Recently, it has
been discovered that opioid receptors are widely dis-
tributed not only in the central but also peripheral nervous
system and in the non-neuronal tissues. There is also
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evidence from animal and human studies for the involve-
ment of peripheral opioid receptors in analgesia, especially
in the presence of inflammation (Sehgal et al. 2011), or
neuropathy (Plein and Rittner 2017).
The nociceptin/orphanin FQ opioid peptide receptor
(NOP receptor) is the most recently discovered member of
the opioid receptor family. Together with its endogenous
ligand–nociceptin, also known as orphanin FQ (N/OFQ), it
forms the fourth member of the opioid receptor family
which is abundantly expressed in various body tissues. A
large body of evidence shows that the activation of
N/OFQ-NOP system regulates functions of the central
nervous system being implicated in feeding, body weight
homeostasis, stress, stress-related psychiatric disorders—
depression, anxiety, drug, and alcohol dependence (Witkin
et al. 2014). Data from preclinical studies are also in line
with these findings showing that N/OFQ plays an important
role in comorbid neuropathic pain and post-traumatic stress
disorder (Zhang et al. 2015), acute and chronic restraint
stress responses (Delaney et al. 2012), depression (Vitale
et al. 2017), and other stress-related conditions (Leggett
et al. 2006; Witkin et al. 2014).
Apart from this, the N/OFQ-NOP pathway is also
involved in the modulation of inflammatory and immune
responses of the body by influencing migration of leuco-
cytes, cytokine secretion, and lymphocyte proliferation.
Recent findings showing the involvement of N/OFQ in
inflammatory responses (Gavioli and Romão 2011) and the
evidence for a role of NOP receptors and N/OFQ in the
modulation of neurogenic inflammation, migraine (Tajti
et al. 2015), and airway tone (Singh et al. 2016) led to the
hypothesis that N/OFQ-NOP system might be an important
drug target for analgesic drugs. This is in part supported by
the previous findings showing that the blockade of NOP
receptors can attenuate inflammation (Gavioli et al. 2015).
On the other hand, this issue is not completely clear and
unequivocally explored as there is also evidence for anal-
gesic efficacy of NOP agonists in neuropathic and
inflammatory pain, both in animal models (Sukhtankar
et al. 2013) and clinical trials (Sałat et al. 2015a).
Cebranopadol (a.k.a. GRT-6005; trans-60-fluoro-40,90-
dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-
1,10(30H)-pyrano[3,4-b]indol]-4-amine) is a dually acting
nociceptin/orphanin FQ and opioid receptor agonist (Ki
(nM)/EC50 (nM)/relative efficacy (%): human NOP
receptor 0.9/13.0/89; human mu-opioid peptide (MOP)
receptor 0.7/1.2/104; human kappa-opioid peptide (KOP)
receptor 2.6/17/67; human delta-opioid peptide (DOP)
receptor 18/110/105) (Linz et al. 2014) that has been
recently developed in Phase 2 clinical trials for painful
diabetic neuropathy or cancer pain (reviewed in Sałat et al.
2015a). It showed analgesic properties in various rat
models of acute thermal pain, i.e., tail-flick model, chronic
inflammatory pain (CFA-induced arthritis model), bone
cancer pain model (Raffa et al. 2017), and neuropathic
pain: chronic constriction injury (CCI) and diabetic neu-
ropathic pain models (Raffa et al. 2017) after intraplantar,
intracerebroventricular, intrathecal, intravenous (Tzschen-
tke et al. 2017), subcutaneous, or oral route (Linz et al.
2014). Compared to selective MOP receptor agonists, ce-
branopadol was more potent in models of chronic
neuropathic than acute nociceptive pain and its duration of
action was long (Linz et al. 2014). Noteworthy, safety
pharmacology studies with cebranopadol demonstrated that
the development of analgesic tolerance in cebranopadol-
treated animals subjected to CCI procedure was delayed as
compared to equi-analgesic doses of morphine (Sałat et al.
2015a), and at analgesic doses, cebranopadol did not cause
respiratory depression in a rat whole-body plethysmogra-
phy model, or motor coordination deficits in the rat rotarod
test (Linz et al. 2014, 2017; Lambert et al. 2015; Günther
et al. 2017).
The data presented above come from rat studies and
there is limited knowledge about antinociceptive properties
of cebranopadol in mice. Moreover, these previous studies
investigated the influence of cebranopadol on tactile allo-
dynia but not thermal (i.e., heat or cold) allodynia and
hyperalgesia. Hence, in the present study, we utilized
mouse models of acute, tonic, and chronic pain induced by
thermal or chemical (inflammatory) stimuli, with a partic-
ular emphasis on pharmacoresistant chronic neuropathic
pain evoked by oxaliplatin. Oxaliplatin is a third-genera-
tion platinum-based anti-tumor drug used to treat advanced
colorectal cancer. Compared to other platinum-based
drugs, it has lower incidence of hematological adverse
effects and gastrointestinal toxicity, but in approximately
95% of patients, oxaliplatin causes severe neuropathic pain
episodes and increased sensitivity to cold (Manji 2013)
which often lead to dose reduction or even treatment dis-
continuation. These neuropathic pain episodes can be
effectively attenuated by l opioid peptide (MOP) and NOP
receptor agonists (Micheli et al. 2015).
In the present study, we investigated the effect of
cebranopadol on cold nociceptive threshold of oxaliplatin-
treated mice. We used two protocols of its administration:
the first one which utilized this drug alone, and the second
one in which cebranopadol was used in combination with
simvastatin. Available data show potential effectiveness of
simvastatin in several animal models of pain (Shi et al.
2011; Miranda et al. 2011; Chen et al. 2013; Mansouri
et al. 2017), including inflammatory (Chen et al. 2013) and
neuropathic pain models (Shi et al. 2011). First, in the
previous studies (Bhalla et al. 2015), simvastatin effec-
tively reversed vincristine-induced neuropathic pain by
anti-inflammatory effects and it was able to attenuate
vincristine-induced increase in myeloperoxidase activity.
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Second, anti-inflammatory and anti-oxidant effects of this
drug also resulted in reduction of cisplatin-induced
nephrotoxicity and hepatotoxicity in rats (Işeri et al. 2007)
and simvastatin protected Sertoli cells against cisplatin
cytotoxicity (Wang et al. 2015). Third, it has been also
shown that simvastatin was able to attenuate neuropathic
pain induced by CCI in rats and it significantly decreased
the ratio of membrane/cytosolic RhoA by reducing RhoA/
LIMK/cofilin pathway activity (Qiu et al. 2016). Further-
more, it exerted antihyperalgesic and antiallodynic effects
through the inhibition of spinal RhoA activation and its
daily intrathecal administration before nerve injury pre-
vented the development of neuropathy in nerve-ligated
mice (Ohsawa et al. 2016). Interestingly, the RhoA-de-
pendent pathway is implicated in the regulation of
Transient receptor potential melastatin subtype 8
(TRPM8), a cold-sensing cation channel (Sun et al. 2014)
which is also required for cold-related symptoms of
oxaliplatin-induced peripheral neurotoxicity (Knowlton
et al. 2011; Kono et al. 2012). Taken together, these data
clearly suggest that statins are effective in neuropathic pain
conditions and they might modulate pain sensitivity of
cold-exposed subjects. This justifies the rationale to
undertake this part of research which aimed to assess if
combined use of simvastatin and cebranopadol could
attenuate cold hypersensitivity of oxaliplatin-treated mice.
Materials and methods
Animals and housing conditions
Experiments were carried out at the Department of Phar-
macodynamics, Faculty of Pharmacy, Jagiellonian
University Medical College in Krakow. The investigators
involved in behavioral assays were blinded to the experi-
mental groups to avoid potential bias in data recording.
Adult male Albino Swiss (CD-1) mice weighing 18–22 g
were purchased from the Animal Breeding Farm of the
Jagiellonian University Faculty of Pharmacy. Before
behavioral tests, the animals were kept in groups of 10
mice in standard plastic cages and housed under controlled
conditions (room temperature of 22 ± 2 C, light/dark
(12:12) cycle, lights on at 8.00 AM, humidity 50–60% and
free access to food and water). Experimental groups con-
sisted of 8–10 animals/dose. For the tests, the animals were
selected randomly. After the assay, the mice were imme-
diately euthanized by cervical dislocation. All experiments
were performed between 9 AM and 3 PM. The procedures
for in vivo tests were approved by the Local Ethics Com-
mittee of the Jagiellonian University in Krakow (Approval
No. 4/2016; 22.03.2016) and the treatment of animals was
in full accordance with ethical standards laid down in
respective Polish and EU regulations (Directive No.
86/609/EEC).
Chemicals
Cebranopadol and morphine hydrochloride were purchased
from MedChem Express (NJ, USA) and Polfa Kutno
(Poland), respectively. These drugs at a fixed dose of
10 mg/kg were administered subcutaneously before
behavioral tests. This dose was selected based on our
previous pilot study which revealed that full antinocicep-
tive efficacy of morphine used as a reference drug was
observed at doses 6–10 mg/kg. For in vivo tests, cebra-
nopadol was prepared in a mixture of 100% DMSO
(Polskie Odczynniki Chemiczne, Poland) and 0.9% saline
(1:1), then being diluted in saline to achieve a proper
concentration and was injected 120 min before testing (for
details, see Sect. 3.1.1). Morphine hydrochloride was dis-
solved in 0.9% saline solution and it was administered
60 min before the tests. Control animals received vehicle.
Acetic acid, ethanol, 0.9% natrium chloride solution, 5%
glucose solution, and 37% formaldehyde solution were
provided by Polskie Odczynniki Chemiczne (Poland).
Capsaicin, simvastatin, and oxaliplatin were purchased
from Sigma-Aldrich (Germany). For the in vivo experi-
ments, capsaicin was dissolved in ethanol (100%) at 5% of
the final desired volume, and then, 0.9% saline was added.
This mixture was vortexed for 10 min (Sałat et al. 2014).
Simvastatin was suspended in 0.9% saline solution. The
dose of simvastatin used in the present research (100 mg/
kg, p.o.) was chosen on the basis of the previous studies
published by other authors (Mansouri et al. 2015).
Behavioral tests
Acute pain models (thermal pain, inflammatory,
and chemogenic pain models)
Thermal pain—hot plate test Antinociceptive properties
of cebranopadol and morphine in the hot plate test were
assessed as described previously (Eddy and Leimbach
1953) with some minor modification (Sałat et al. 2015b).
Briefly, 1 day before the proper pharmacological experi-
ment, the animals were tested to establish baseline pain
sensitivity threshold (baseline latency) for each animal. For
further pain tests, only mice with baseline latencies B 20 s
were used. On the test day, the animals were subcuta-
neously treated either with the test drugs, or vehicle 60 min
before placing the animal on a hot/cold plate apparatus
(Bioseb, France). This apparatus can generate heat or cold
and is supplied with a temperature controller that maintains
surface temperature to a set point. Herein, the temperature
was set at 55–56 C. Latency time to pain reaction, i.e., the
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time until the animal licked its hind paws or jumped was
recorded by means of a stop-watch (Q&Q HS-46, Japan,
precision: 1/100 s). In this assay, a cut-off time (60 s) was
enforced to avoid paw tissue damage, and mice not
responding within 60 s were removed from the apparatus
and assigned a score of 60 s.
Inflammatory acute pain—writhing test In this test, mice
were placed individually into glass beakers and were
allowed to habituate for the next 30 min. Then, each mouse
was weighed, injected with the test compound or vehicle,
and then placed back into the glass beaker for 60 min. To
induce inflammatory pain, 0.9% acetic acid solution pre-
pared in saline was injected by the intraperitoneal route.
Mice were placed in the beakers once again and were
observed continuously for the next 30 min. Stereotypical
writhes (lengthwise constrictions of the torso with a con-
comitant concave arching of the back) were counted over
this period in drug-treated and control mice (Sałat et al.
2013a).
Neurogenic pain—capsaicin test After the adaptation
period (15 min), 1.6 lg of capsaicin dissolved in 20 ll of a
mixture containing 0.9% saline and ethanol (5% of the final
volume) was injected intraplantarly in the ventral surface
of the right-hind paw of each mouse. The animals were
observed individually for 5 min following capsaicin
injection. In all experimental groups, the amount of time
spent on licking, biting, or lifting the injected paw was
recorded with a chronometer and was considered as an
indicator of nociception (Sałat et al. 2014).
Inflammatory tonic pain model—formalin test
In rodents, the injection of diluted formalin solution evokes
a biphasic nocifensive behavioral response (licking or bit-
ing the injected paw) of experimental animals. The first
(acute) nociceptive phase of the test lasts for 5 min, whilst
the second (late) one occurs between 15 and 30 min after
formalin injection. In this assay, 20 ll of 5% formalin
solution was injected into the dorsal surface of the right-
hind paw of each mouse. Then, the mice were placed
separately in glass beakers and were observed for the next
30 min. Total time spent on licking or biting the formalin-
treated paw was measured during the first 5 min of the test,
and then between 15 and 30 min of the test in drug-treated
and vehicle-treated mice (Sałat et al. 2015b).
Chemotherapy-induced neuropathic pain model
Induction phase To develop chemotherapy-induced
peripheral neuropathy (CIPN) and neuropathic pain mice
were injected intraperitoneally with a single dose of
oxaliplatin (10 mg/kg prepared in 5% glucose solution).
Control mice received 5% glucose solution as vehicle. Pain
threshold of experimental animals was assessed using the
cold plate test 3 h and 7 days after oxaliplatin adminis-
tration to establish its effect on acute-phase and late-phase
cold allodynia, respectively.
Influence on cold allodynia (cold plate test)—single-drug
administration protocol The cold plate test was per-
formed using the hot/cold plate apparatus set at 2 C. In
this assay (Fig. 1a), the animals were tested first to obtain
baseline latencies to pain reaction (i.e., lifting, biting,
shaking of hind paws, jumping, and movement deficits)
before oxaliplatin injection (referred to as latencies ‘before
oxaliplatin’). Then, oxaliplatin was injected and latencies
to pain reaction were measured again (referred to as ‘pre-
drug latencies’). Subsequently, test drugs were adminis-
tered and post-drug latencies were measured again. In this
assay, a cut-off time of 60 s was established to avoid
potential paw tissue damage and animals not responding
within 60 s were removed from the apparatus and assigned
a score of 60 s.
Influence on cold allodynia (cold plate test)—combined
drug administration protocol (simvastatin and cebra-
nopadol) In the cold plate test, we additionally
investigated the antiallodynic activity of cebranopadol used
in combination with simvastatin. The protocol of the
administration of these both drugs (alone or in combina-
tion) is shown in Fig. 1. It served to establish whether
cebranopadol could enhance antiallodynic properties of
simvastatin in the oxaliplatin model of neuropathic pain.
Influence on motor coordination—rotarod test
Before the test, the animals were trained for 3 consecutive
days on the rotarod apparatus (Rotarod apparatus, May
Commat RR0711, Turkey; rod diameter: 2 cm) that was
rotating at a fixed speed of 18 rotations per minute (rpm).
In each session, the mice were placed on the rotating rod
for 3 min with an unlimited number of trials. The proper
experiment was performed 24 h after the last training
session. After the administration of the test drugs or vehi-
cle, the mice were tested on the rod that revolved at 6, 18,
or 24 rpm. Motor impairments in mice were defined as the
inability to remain on the rotarod apparatus for 1 min. The
results are expressed as the mean time spent on the rotarod
(Sałat et al. 2015b).
Data analysis
Data analysis was carried out using GraphPad Prism soft-
ware (v.5.0, CA, USA). Numerical results are expressed as
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the mean ± SEM. Statistical analysis was carried out using
one-way analysis of variance (ANOVA), followed by
Tukey’s, or Dunnett’s post hoc comparisons, or repeated-
measures analysis of variance, followed by Bonferroni’s
multiple comparison. P\ 0.05 was considered significant.
Results
Acute pain models
Thermal acute pain—hot plate test
To establish at which time-points subcutaneous cebranopadol
exerts antinociceptive activity, the mouse hot plate test was
used. In this assay, an overall effect of treatment was observed
(F[4,28] = 6.676, p\ 0.001). The post hoc analysis revealed
that the antinociceptive activity of cebranopadol was signifi-
cant 90 min and 120 min after its administration (p\ 0.01
and p\ 0.001, respectively; Fig. 2). Taking this into con-
sideration, further pain tests were performed 90 and 120 min
after cebranopadol injection.
Previously obtained results for subcutaneous morphine in
the hot plate test performed under the same experimental
conditions (Sałat et al. 2009) demonstrated its significant
antinociceptive properties. The dose of 6 mg/kg was highly
effective and this activity was noted earlier than that of
cebranopadol (between 30 and 60 min after administration).
Inflammatory acute pain—writhing test
As shown in Fig. 3a, cebranopadol and morphine were
equally effective in reducing acetic acid-induced writhing
behavior (F[2,20] = 52.86, p\ 0.0001).
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Neurogenic pain—capsaicin test
In the intraplantar capsaicin test (Fig. 3b), the pretreatment
with cebranopadol and morphine completely abolished the
licking response of capsaicin-treated mice
(F[2,21] = 50.18, p\ 0.0001). This confirmed strong
antinociceptive properties of both agents in this pain
model.
Inflammatory tonic pain model—formalin test
The results obtained in the first phase of the intraplantar
formalin test confirmed that both drugs were able to
attenuate neurogenic pain (F[2,21] = 14.92, p\ 0.0001)
with morphine being slightly more effective (Fig. 4a). The
antinociceptive activity of both tested agents was also
shown in the second (inflammatory) phase which demon-
strated that cebranopadol and morphine significantly (at
p\ 0.01 and p\ 0.001, respectively) reduced pain
responses in formalin-treated animals (F[2,21] = 11.81,
p\ 0.001; Fig. 4b).
Chemotherapy-induced neuropathic pain model
Influence on cold allodynia (single-drug administration
protocol)
In this experiment, an overall effect of treatment was
observed (F[16,127] = 15.58, p\ 0.0001). As shown in
Fig. 5, during the early phase cold allodynia, both cebra-
nopadol and morphine demonstrated strong and
statistically significant (p\ 0.01) antiallodynic properties.
Their antiallodynic activity was also confirmed during the
late phase of cold allodynia—7 days after oxaliplatin
injection (significant at p\ 0.05 and p\ 0.01 for cebra-
nopadol and morphine, respectively).
Influence on cold allodynia (combined treatment protocol:
cebranopadol and simvastatin)
Preliminary experiments (data not shown) performed using
the cold plate test in mice not treated with oxaliplatin (i.e.,
non-neuropathic mice) revealed overall effects of single-
dose and repeated-dose simvastatin treatments (single-dose
simvastatin: F[5,32] = 8.366, p\ 0.0001; repeated-dose
simvastatin: F[7,46] = 4.209, p\ 0.01). Post hoc analyses
Fig. 2 Antinociceptive activity of subcutaneous cebranopadol in the
mouse hot plate test measured at various time-points. Results are
shown as latency time to pain reaction (±SEM) in response to thermal
stimulation (temperature of 55–56 C). Statistical analysis: repeated-
measures analysis of variance, followed by Bonferroni’s multiple
comparison. Significance vs. pre-drug latency: **p\ 0.01,
***p\ 0.001
Fig. 3 Antinociceptive activity of cebranopadol (CEB) and morphine
(MOR) in the acetic acid-induced writhing test (a) and in capsaicin-
induced neurogenic pain model (b). Results are shown as the mean
number of writhes (±SEM) (a), or duration of the licking/biting
response (±SEM) (b). Statistical analysis: one-way analysis of
variance, followed by Dunnett’s post hoc test. Significance vs.
vehicle-treated mice: ***p\ 0.001
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revealed that there were significant (p\ 0.001) differences
between the latencies of naı̈ve mice and those of mice
treated with a single dose of simvastatin. The latencies of
the latter group were significantly reduced as compared to
naı̈ve mice. Similar effects were observed in mice repeat-
edly treated with simvastatin (p\ 0.01 vs. naı̈ve mice). No
significant differences were noted when the latencies of
mice treated with single-dose and repeated-dose simvas-
tatin were compared (F[5,46] = 0.3205, p[ 0.05).
The administration of oxaliplatin significantly reduced
cold sensitivity threshold in mice (F[8,31] = 11.48,
p\ 0.0001). Significantly decreased latency time to pain
reaction (p\ 0.001 vs. values before oxaliplatin adminis-
tration) was observed 3 h after oxaliplatin injection. This
indicated for the development of cold allodynia in oxali-
platin-treated, neuropathic mice (Fig. 6a). Cold allodynia
was maintained even for 7 days (significant at p\ 0.05 vs.
values before oxaliplatin administration).
On day 1 in neuropathic (oxaliplatin-treated) mice,
simvastatin administration (black bars—Figs. 6b–d:
sim ? oxa) did not influence cold allodynia significantly,
although we observed a slight prolongation of latency time
Fig. 4 Antinociceptive activity of cebranopadol (CEB) and morphine
(MOR) in the tonic pain model (i.e., the intraplantar formalin test).
Influence on the first, neurogenic phase responses (a) and on the
second, inflammatory phase responses (b). Statistical analysis: one-
way analysis of variance, followed by Dunnett’s post hoc test.
Significance vs. vehicle-treated mice: **p\ 0.01, ***p\ 0.001
Fig. 5 Antiallodynic activity of cebranopadol and morphine in
oxaliplatin-induced neuropathic pain model. Cold allodynia was
measured using the cold plate test in the early phase (3 h after
oxaliplatin administration) and in the late phase (7 days after
oxaliplatin administration). Results are shown as latency time to pain
reaction (±SEM) in response to thermal stimulation (temperature of
2 C). Statistical analysis: one-way analysis of variance, followed by
Tukey’s post hoc test. Significance vs. latencies of vehicle-treated
mice (i.e., mice not treated with oxaliplatin): ###p\ 0.001, and vs.
pre-drug latencies at the respective time-point: *p\ 0.05,
**p\ 0.01, ***p\ 0.001
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to pain reaction after a single dose of this drug. Notewor-
thy, comparing pre-drug latencies in the cold plate test
(grey bars—Figs. 6b–d: sim ? oxa) during the early (on
day 1) and the late (on day 7) phases of cold allodynia to
the latency of untreated controls (a white bar—Figs. 6b–d:
sim ? oxa), it can be concluded that the repeated (7-day)
administration of simvastatin partially reversed the
decrease of pain threshold caused by oxaliplatin and par-
tially restored it to values of mice not treated with
oxaliplatin.
In general, the use of cebranopadol as ‘add-on’ therapy
with simvastatin in neuropathic, oxaliplatin-treated mice
showed no benefits. However, we noted some differences
among groups treated with ‘add-on’ cebranopadol used
simultaneously (F[9,70] = 6.657, p\ 0.0001; Fig. 6B:
sim ? ceb), 4 h (F[9,65] = 11.37, p\ 0.0001; Fig. 6C:
sim ? ceb (4 h)) or 6 h (F[9,65] = 9.875, p\ 0.0001;
Fig. 6d: sim ? ceb (6 h)) after simvastatin. Post hoc
analyses showed no significance of these results but
interestingly, we observed a trend towards the prolongation
of latency time to pain reaction in mice treated with
combined simvastatin and cebranopadol, when cebra-
nopadol was administered 4 h (Fig. 6c), or 6 h after
simvastatin (Fig. 6d), but not if these two drugs were given
simultaneously (Fig. 6b).
Influence on motor coordination (rotarod test)
In the rotarod test, neither cebranopadol nor morphine
influenced animals’ motor coordination at 6, 18, or 24 rpm
which means that the drugs tested did not cause motor
deficits in mice.
Fig. 6 Influence of oxaliplatin (10 mg/kg, i.p.; OXA), simvastatin
(100 mg/kg, oral route; SIM) alone, or in combination with subcu-
taneous cebranopadol (10 mg/kg, s.c.; CEB) on cold sensitivity
threshold and cold allodynia measured in the cold plate test in
oxaliplatin-induced neuropathic pain model. Effect of oxaliplatin on
the development of cold allodynia (a). Effect of 7-day administration
of oral simvastatin alone (OXA ? SIM), or in combination with
single-dose cebranopadol added on day 7: simultaneously
(b OXA ? SIM ? CEB), 4 h (c OXA ? SIM ? CEB (4 h)), or
6 h (d OXA ? SIM ? CEB (6 h)) after simvastatin. Results are
shown as latency time to pain reaction (±SEM) in response to thermal
(cold) stimulation (2 C). In this test, the data were collected at two
time-points: on day 1 to measure the latencies to pain reaction during
the acute-phase cold allodynia that developed after oxaliplatin
injection, and on day 7 to measure the latencies to pain reaction
during the late-phase cold allodynia. Day 1: grey bars indicate
baseline latencies of oxaliplatin-treated mice measured before drug
treatment (i.e., before vehicle or simvastatin administration; defined
as ‘pre-drug’) and black bars depict latencies after drug administra-
tion (i.e., after vehicle or simvastatin administration; referred to as
‘post-drug’ values). Day 7: grey bars indicate baseline latencies of
oxaliplatin-treated mice measured before drug treatment (i.e., before
vehicle, simvastatin or cebranopadol administration; defined as ‘pre-
drug’) and black bars depict latencies after drug administration (i.e.,
after vehicle, simvastatin only, or simvastatin and cebranopadol
administration; referred to as ‘post-drug’ values). A detailed protocol
used is also shown in Fig. 1. Statistical analysis: one-way analysis of
variance, followed by Tukey’s post hoc test. Significance vs. latency
to pain reaction before oxaliplatin injection: ## p\ 0.01, ###
p\ 0.001.
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Discussion
In this study, we implemented mouse models of acute,
tonic, and chronic pain to assess antinociceptive properties
of cebranopadol, a dually acting nociceptin/orphanin FQ
and opioid receptor agonist. Antinociceptive efficacy of
cebranopadol was compared to that of morphine used at an
equal dose. A summary of results obtained for both drugs
in various mouse pain tests is presented in Table 1.
In the hot plate test, both cebranopadol and morphine
demonstrated strong and statistically significant antinoci-
ceptive properties. Of note, the activity of cebranopadol
was delayed as compared to that previously shown for
morphine (90–120 min vs. 30–60 min for cebranopadol
and morphine, respectively) (Gades et al. 2000; Sałat et al.
2012). The hot plate assay is a rodent model of acute pain.
The paws of mice are very sensitive to heat at temperatures
that are not harmful to the skin. The characteristic
responses such as jumping, licking of the paws are of
central origin and it is thought that drugs with antinoci-
ceptive properties in the hot plate test act primarily in the
spinal medulla and/or higher central nervous system levels
(Vogel and Vogel 1997). In this assay, peripherally acting
analgesics are generally not active (Vogel and Vogel
1997). Thus, the results obtained in the present study
confirmed the role of central opioidergic system in medi-
ating analgesia caused by cebranopadol (and morphine).
Available literature data indicate that functional NOP
and MOP receptors are expressed not only at spinal and
supraspinal sites of the ascending and descending pain
pathways but also in the periphery. NOP receptors and their
ligand—N/OFQ have been found in many peripheral
organs (e.g., airways and cardiovascular system) and in the
immune system in rodents and humans (Schröder et al.
2014). In a rat model of inflammatory pain (i.e., trini-
trobenzene sulfonic acid (TNBS)-induced colonic
hyperalgesia), N/OFQ demonstrated antihypersensitive
effects after peripheral administration and it was
antinociceptive in the capsaicin test in mice (Sakurada
et al. 2005). N/OFQ exerted analgesic properties in the tail-
flick test in rats (Xu et al. 1996; Tian et al. 1997) and mice
(King et al. 1997). Moreover, spinal N/OFQ potentiated
analgesia caused by systemic morphine (Tian et al. 1997),
while a selective non-peptide NOP receptor agonist, SCH-
221510, showed anti-inflammatory and analgesic proper-
ties in a mouse model of TNBS-induced inflammatory
bowel disease after systemic administration (Sobczak et al.
2013, 2014).
In line with these findings, in our present study, both
cebranopadol and morphine attenuated chemogenic,
inflammatory acute pain responses induced by acetic acid.
Since the writhing test is regarded a rodent model of pain
mediated by peripheral mechanisms related to inflamma-
tion (Vogel and Vogel 1997), it seems plausible that
peripheral NOP and MOP receptors might play a role in the
observed activity of both drugs. The involvement of NOP
receptors in the pathophysiology of inflammation, arterial
hypertension, and cardiac or brain circulatory ischemia has
been reported previously (reviewed in Schröder et al.
2014). In the rat model of carrageenan-induced inflam-
mation, i.t. N/OFQ inhibited thermal hyperalgesia
(Yamamoto et al. 1997b; Hao et al. 1998), and NOP
receptors and their endogenous ligand—N/OFQ modulated
neurogenic inflammation and other functions, such as air-
way tone and caliber (Singh et al. 2016).
The influence of cebranopadol and morphine on
peripherally expressed opioid receptors might also explain
their activity observed in the capsaicin test. This pain test
reflects acute inflammatory pain responses related to neu-
rogenic inflammation. Capsaicin is an exogenous activator
of the TRPV1 channels present in sensory neurons, mainly
in C-fibers and, to a lesser extent, Ad. It shows a biphasic
effect, i.e., it stimulates TRPV1 located in sensory neurons,
resulting in a rapid phase of neurogenic pain with a burning
sensation, local vascular and extravascular responses, after
which persistent desensitization with concomitant long
lasting analgesia appears (reviewed in Sałat et al. 2013b;
Marwaha et al. 2016). Previously, it was shown that NOP
receptor activation abolished capsaicin-induced contraction
of guinea pig airways (Shah et al. 1998; Corboz et al.
2000), reduced capsaicin-induced bronchoconstriction, and
increased airway hyper-responsiveness in ovalbumin-
Table 1 Comparison of antinociceptive properties of cebranopadol and morphine in mouse models of pain
Pain test Efficacy: cebranopadol (CEB) vs. morphine (MOR) Figure
Hot plate test (acute thermal pain) CEB = MORa Figure 2
Writhing test (acute inflammatory pain) CEB = MOR Figure 3a
Capsaicin test (acute neurogenic pain) CEB = MOR Figure 3b
Formalin test (tonic—neurogenic and inflammatory pain) CEB\MOR Figure 4a,b
Cold plate test (oxaliplatin-induced neuropathic pain) CEB C MOR Figure 5
aData from Gades et al. 2000; Sałat et al. 2012
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sensitized mice (D’Agostino et al. 2010). Of note, in the
peripheral nervous system, N/OFQ inhibited neurotrans-
mitter release (Giuliani et al. 2000) and inhibited substance
P-mediated nociception in mice (Inoue et al. 1999). Con-
sidering an important role of substance P in neurogenic
inflammation caused by capsaicin, the antinociceptive
activity of cebranopadol in the capsaicin test can be
explained in terms of its influence on neurogenic
inflammation.
In the formalin test—a tonic pain model, cebranopadol
was slightly less active than morphine. This was observed
both in the acute (neurogenic) phase, and in the late (in-
flammatory) phase of this test. Intraplantar formalin
induces chemogenic pain that results from neurogenic
inflammation, sensory C-fibers activation, as well as sen-
sitization within the spinal cord dorsal horn and the brain
(Hunskaar and Hole 1987; Tjølsen et al. 1992; Yashpal and
Coderre 1998), but there is also evidence that formalin is a
potent stimulator of TRPA1 channels (McNamara et al.
2007; Nassini et al. 2015; Sałat and Filipek 2015). Our
present study shows that NOP/MOP receptor activation
might also mediate analgesia in the formalin test. It was
previously demonstrated that in the formalin test, N/OFQ
was antinociceptive after intrathecal administration,
whereas it exerted pronociceptive effects and antagonized
opioid analgesia when administered intracerebroventricu-
larly (Erb et al. 1997; Yamamoto et al. 1997a; Zhu et al.
1997; Hao and Ogawa 1998; Wang et al. 1999). This
bidirectional and site-specific modulation of nociception
was also confirmed in the mouse formalin test in which
UFP-101, a peptide antagonist selective for NOP receptors,
exerted antinociceptive and pronociceptive effects after
intracerebroventricular and intrathecal administration,
respectively (Rizzi et al. 2006). Antihyperalgesic activity
in the formalin test was also observed after systemic
administration of selective, non-peptide NOP receptor
agonist GRT-TA2210 (Linz et al. 2013).
In animals treated with oxaliplatin, the pain threshold
for cold nociception is significantly lower as compared to
non-treated mice. This was confirmed in our study in the
cold plate test and indicated for the development of cold
allodynia in oxaliplatin-treated mice. Recently, it has been
shown that tactile allodynia and cold allodynia in rodents
treated with oxaliplatin are mediated by TRPA1 stimula-
tion (Nassini et al. 2011; Zhao et al. 2012; Sałat et al.
2013b; Marwaha et al. 2016) and a single dose of oxali-
platin induces acute cold hypersensitivity associated with
an enhanced responsiveness of TRPA1 channels (Zhao
et al. 2012). The antiallodynic activity of cebranopadol
(and morphine) in the oxaliplatin model of neuropathic
pain, in particular in the acute phase, together with the
results obtained in the formalin test indicate that both drugs
tested are able to attenuate TRPA1-mediated pain
responses in mice. To the best of our knowledge, this drug
has not been evaluated in these pathological conditions
previously and our present study confirmed its potential
utility for patients suffering from oxaliplatin-induced neu-
ropathic pain. This is a potentially interesting finding as
classical opioid drugs have limited efficacy in neuropathic
pain conditions and they are regarded the third-line (mor-
phine) or the second-line (tramadol) treatment for
neuropathic pain (Finnerup et al. 2015), which is in part
due to a diversity of mechanisms underlying the develop-
ment of neuropathic pain (Torrance et al. 2013).
The expression of NOP receptors is up-regulated in
chronic (neuropathic and inflammatory) pain conditions
(Briscini et al. 2002; Chen and Sommer 2006; Schröder
et al. 2014) and N/OFQ showed antihypersensitive effects
in various rodent models of neuropathic pain, including rat
CCI model (Yamamoto et al. 1997b; Corradini et al. 2001;
Courteix et al. 2004), spinal nerve ligation (SNL) model
(Ju et al. 2013), as well as the mouse diabetic neuropathic
pain model (Kamei et al. 1999). In addition, some non-
peptide NOP receptor agonists (SR14150 and SR16835)
displayed NOP receptor-dependent antiallodynic activity in
SNL model in mice (Khroyan et al. 2011), whereas in the
mouse CCI model, GRT-TA2210 and Ro65-6570 demon-
strated strong antiallodynic effects after spinal, supraspinal,
and systemic administration (Linz et al. 2013).
Strong anti-inflammatory activity of cebranopadol, as
well as the previously reported role of MOP, NOP recep-
tors and N/OFQ in the attenuation of inflammation led us to
investigate, if cebranopadol might potentiate/modulate the
antiallodynic activity of other drugs with anti-inflammatory
properties in chronic pain conditions. For this purpose, we
chose the oxaliplatin neuropathic pain model and we used
simvastatin as a potential novel treatment option for this
pharmacoresistant pain type. Among numerous pathome-
chanism inflammation has been discovered as one of the
key factors underlying neurotoxicity of oxaliplatin (Mas-
sicot et al. 2013; Waseem and Parvez 2016). Anti-
inflammatory and analgesic properties of simvastatin in
neuropathic pain conditions have been widely described in
the literature (Miranda et al. 2011; Jaiswal and Sontakke
2012). Moreover, it has been shown that statins have pro-
tective effect on ultrastructural alterations induced by cold
stress in rats (Bombig et al. 2003). They are also able to
attenuate mitochondrial injury induced by cold exposure,
inhibit the elevation of blood pressure in cold-treated mice
via the downregulation of Bcl-2 pathway (Liang et al.
2017), and they are effective in the attenuation of Ray-
naud’s phenomenon (Baumhäkel and Böhm 2010). This
activity of simvastatin is complex and it involves various
pleiotropic effects, such as modulation of endothelial
functions and Rho-kinase inhibition, which, in turn, affects
TRPM8 activity (Sun et al. 2014). Taken together, these
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data clearly suggest that statins might modulate body
functioning of cold-exposed subjects.
In the cold plate test in oxaliplatin-treated mice com-
pared to non-treated controls, a significant reduction of
latency time to pain reaction was observed both 3 h and
7 days after its administration. This indicated the devel-
opment of cold allodynia in oxaliplatin-treated mice. Cold
allodynia in neuropathic mice was not influenced by a
single dose of simvastatin administered alone (see results
for the early phase), but in contrast to this, a 7-day treat-
ment with this drug partially reversed allodynia induced by
cold and the difference between latencies of non-neuro-
pathic mice and oxaliplatin ? repeated simvastatin-treated
mice was no longer significant. Thus, it might indicate that
the repeated administration of simvastatin elevated pain
threshold of animals with CIPN. The addition of cebra-
nopadol to simvastatin did not demonstrate additional
benefits. Of note, a simultaneous treatment with both drugs
reduced latency time to pain reaction. Numerous studies
have shown that the hot/cold plate test latencies might
decrease with a repeated testing and this decrease may
involve learning abilities, differences in animals’ weight,
habituation time, and other unknown factors (Czopek et al.
2016). Of note, cebranopadol added to oxaliplatin ? re-
peated simvastatin-treated mice 4 h or 6 h after the last
dose of simvastatin (day 7) did not reduce the latency time
to pain reaction and a tendency towards the prolongation of
this parameter was noted. This is an interesting finding
which requires further studies, but it may potentially sug-
gest some pharmacodynamic interaction at the common
site of action.
The rotarod test was involved for a proper interpretation
of data obtained in pain tests to avoid the possibility of
false positive results (Vogel and Vogel 1997). The results
of our study showed no motor deficits in mice treated with
cebranopadol and this finding is in line with the previous
literature data (Bird and Lambert 2015).
To conclude, in this study using mouse models of acute,
tonic, and chronic pain, we demonstrated antinociceptive and
antiallodynic properties of cebranopadol—a novel, first-in-
class agonist at nociceptin/orphanin FQ and opioid receptors.
Of note, the antiallodynic activity of cebranopadol in neuro-
pathic pain related to CIPN was shown for the first time,
indicating a potential novel treatment option for this type of
chronic pain. Apart from this, the results from our present
study suggest that NOP receptors might be an important drug
target for analgesics used not only in neuropathic pain con-
ditions but also in inflammatory pain. This is of particular
relevance in terms of pharmacoresistance of these types of
chronic pain to currently available analgesic drugs.
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Courteix C, Coudoré-Civiale MA, Privat AM et al (2004) Evidence
for an exclusive antinociceptive effect of nociceptin/orphanin
FQ, an endogenous ligand for the ORL1 receptor, in two animal
models of neuropathic pain. Pain 110:236–245. doi:10.1016/j.
pain.2004.03.037
Czopek A, Sałat K, Byrtus H et al (2016) Antinociceptive activity of
novel amide derivatives of imidazolidine-2,4-dione in a mouse
Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor… 371
123
model of acute pain. Pharmacol Rep 68:529–535. doi:10.1016/j.
pharep.2015.12.007
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